Replies to post #188 on Aptose Biosciences Inc (APTO)

[Tartiaboy]

The IDH1/IDH2 inhibitors are limited. Yes they generate CRs, but most AML patients have multiple mutations, not just IDH1 or IDH2. They are very susceptible to relapse. I believe that TUSP will be much more effective in first line AML if it proves to be safe with HMA + Ven (which I expect). I expect the range of AML patients that will respond to the triplet to include the IDH2 and possible the IDH1mut patients.